WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

Firm News

Tokai Pharmaceuticals Inc. and Otic Pharma Ltd., a privately held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose and throat, announced that the two companies—together with the shareholders of Otic Pharma—have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai.

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

Read Tokai Pharmaceuticals' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.